UPCHealthcare · Drug Manufacturers - Specialty & GenericUPC Stock Forecast: Universe Pharmaceuticals, Inc. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 34 of 100 as at 12 Sept 2026 — in the lower half.
UPC stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Universe Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (88): Smaller than most of the companies we track.
Volatility (9): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
UPC stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on UPC, reported as data — targets and ratings, the market's view beside the model's.
We don’t hold enough price history for this company yet.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. UPC appears on the weeks it earns a place.
UPC analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Universe Pharmaceuticals, Inc. (UPC) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −0.6×
- Price / sales
- 1.2×
- Price / book
- 0.0×
- EV / EBITDA
- 10.6×
Cheaper than 80% of US stocks
Cheaper than 65% of US stocks
Cheaper than 91% of US stocks
Cheaper than 36% of US stocks
- Revenue growth (YoY)
- −1.3%
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- −16.6%
- Net margin
- −10.9%
Higher than 25% of US stocks
Higher than 22% of US stocks
Higher than 19% of US stocks
- Return on equity
- −3.5%
- Return on assets
- −1.7%
- Dividend yield
- —
Higher than 40% of US stocks
Higher than 38% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
Universe Pharmaceuticals, Inc. (UPC) statistics: revenue, profit & scale
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Universe Pharmaceuticals, Inc. has a market value of $21.9M and an enterprise value of −$17.0M.
Trailing P/E: −0.6×.
Universe Pharmaceuticals, Inc. employs 216 people.
Data provided by Twelve Data
UPC vs competitors
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Universe Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Frequently asked questions about UPC stock
How does Ticker Nerd's model rank UPC?
As at 12 Sept 2026, Universe Pharmaceuticals, Inc. ranks 34 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (88 of 100).
What is the UPC stock forecast for 2030?
No analyst covering Universe Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for UPC are extrapolating price history, which says nothing about the business.
What does Universe Pharmaceuticals, Inc. do?
Universe Pharmaceuticals Inc. Class A Ordinary Shares represents the equity of a China-based pharmaceutical company focused on the manufacturing, marketing, sales, and distribution of traditional Chinese medicine derivative products.
About Universe Pharmaceuticals, Inc.
Universe Pharmaceuticals Inc. Class A Ordinary Shares represents the equity of a China-based pharmaceutical company focused on the manufacturing, marketing, sales, and distribution of traditional Chinese medicine derivative products. The company also offers biomedical drugs, medical instruments, traditional Chinese medicine pieces, and dietary supplements sourced from third-party manufacturers. Its product portfolio is designed to address common health conditions, including chronic ailments associated with aging, as well as cold and flu needs. Operating through its subsidiaries, Universe Pharmaceuticals serves customers in domestic and international markets and participates in the broader healthcare supply chain through production, distribution, and commercialization activities. Headquartered in Ji’an, Jiangxi, China, the company issues Class A ordinary shares as part of a dual-class share structure that is used in its corporate governance framework.
CEO Mr. Gang Lai · 216 employees · China · https://www.universe-pharmacy.com